Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
She brings extensive expertise in managing global and domestic procurement operations
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Subscribe To Our Newsletter & Stay Updated